Kimberly-clark Worldwide, Inc.

Robert B Johnson

Stephanie Michelle Martin

Lei Huang

Shu-Ping Yang

Sharon Linda Greene

Yanbin Huang

Curtis Sayre

Julie M Villanueva

John Gavin MacDonald

Jason Lye

Alison Salyer Bagwell

Kelly Davis Arehart

Sohail Malik

Rameshbabu Boga

Ilona F Weart

Allison Salyer Bagwell

Kelly Arehart

Sharon Greene

A mucosal formulation for administration to mucosal membranes, such as in the mouth, nasal passage, stomach, vagina, etc., is disclosed. The mucosal formulation contains a lipid-pharmaceutical agent complex formed from phospholipids possessing a hydrophobic moiety that orients into a hydrophobic phase and a polar head moiety that orients towards the aqueous phase (i.e., 'amphipathic' lipids). When placed in an aqueous medium (e.g., vaginal fluid), the phospholipids form liposomes or other small lipid vesicles (e.g., micelles) that may then be used to deliver pharmaceutical agents into a living organism.

Mucosal formulation

A vaginal treatment composition that rapidly forms a gel when placed into contact with monovalent or polyvalent cations, such as sodium (Na) and calcium (Ca) cations naturally found in vaginal mucosa, is provided. The gel may form in less than about 1 hour, in some embodiments less than about 1 minute, and in some embodiments, less than about 30 seconds. Among other things, such rapid gelation reduces the likelihood of leakage during use. In addition, because the gel may form intravaginally, it is more likely to retain its structure and shape over an extended period of time. In this manner, the gel may provide the prolonged release of a therapeutic agent that inhibits and/or treats vaginal infection. For instance, the gel may remain within the vagina for about 2 to about 48 hours to provide the desired effect.

Vaginal treatment composition containing xylitol

A vaginal treatment composition that employs a therapeutic agent to inhibit and/or treat vaginal infection is provided. The therapeutic agent is capable of inhibiting and/or killing(e.g.,),(e.g.,), and/or(e.g.,) pathogens. Desirably, such antimicrobial efficacy is achieved without substantially inhibiting the growth of Lactobacillus acidophilus. For instance, sugars and/or sugar alcohols may be employed in the present invention as a therapeutic agent for inhibiting and/or treating vaginal infection. In one particular embodiment, D-xylitol is used as the therapeutic agent.

Xylitol for treatment of vaginal infections

An elastomeric article that contains a chromogen that undergoes a detectable change in color in the presence of one or more microbes is provided. For example, in one embodiment, the chromogen is a solvatochromic dye (e.g., Reichardt's dye) that undergoes a color change in the presence of bacteria or other microbes. More specifically, such dyes may respond to differences in polarity between microbe components (e.g., cell membrane, cytoplasm, etc.) and the environment outside the cell. Alternatively, other mechanisms may be wholly or partially responsible for the interaction between the dye and the microbe, such as acid-base reactions, redox reactions, and so forth.

Detection of microbe contamination on elastomeric articles

The present invention is directed to anti-microbial compositions and methods for treating fungal and yeast infections.

Anti-microbial composition and methods of use thereof

Growing community of inventors

Marietta, GA, United States of America

Robert B Johnson